Closed · RFA-ES-22-006 · CFDA 93.113 · Discretionary

New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $1.8M
Award range
Closed
Status
November 8, 2022
Close date
-
Expected awards

The verdict

New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $1,838,436. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $1.8M
award range
Closed
application status
93.113
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

New Approaches for Incorporating Genetic Dive… is closed (last close November 8, 2022). The parent program page for CFDA 93.113 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed November 8, 2022

Posted Jun 30 Closes Nov 8

Instrument

Grant

Description

This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

Small-business / for-profit corridor · RFA-ES-22-006

New Approaches for Incorporating Genetic Dive… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Environment · Health (ENV;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Parent Grant Program

CFDA 93.113

Biological Response to Environmental Health Hazards

National Institutes of Health

View program →

Agency Contact

NIH OER Webmaster OERWebmaster03@od.nih.gov

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

New Approaches for Incorporating Genetic Dive… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.113 may publish future NOFOs under the same assistance listing. Open program
  • Biological Response to Environmental Health H… indexes 83 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants